Aftovaxpur DOE
inactivated vaccine against foot-and-mouth disease
Table of contents
Overview
Aftovaxpur DOE has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Aftovaxpur DOE
|
| Agency product number |
EMEA/V/C/002292
|
| Active substance |
Maximum three of the following purified, inactivated foot-and-mouth disease virus strains: O1 Manisa ≥ 6 PD50*; O1 BFS ≥ 6 PD50*; O Taiwan 3/97 ≥ 6 PD50*; A22 Iraq ≥ 6 PD50*; A24 Cruzeiro ≥ 6 PD50*; A Turkey 14/98 ≥ 6 PD50*; Asia 1 Shamir ≥ 6 PD50*; SAT2 Saudi Arabia ≥ 6 PD50*; * PD50 – 50% protective dose in cattle as described in Ph. Eur. monograph 0063.
|
| International non-proprietary name (INN) or common name |
inactivated vaccine against foot-and-mouth disease
|
| Species |
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI02AA04
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
| Revision |
8
|
| Date of issue of marketing authorisation valid throughout the European Union |
15/07/2013
|
| Contact address |
55216 Ingelheim am Rhein |
Product information
20/03/2020 Aftovaxpur DOE - EMEA/V/C/002292 - IG/1204/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Active immunisation of cattle, sheep and pigs from 2 weeks of age against foot-and-mouth disease to reduce clinical signs.